| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3ae3d32e12b5bb9d9e0d8e48d7318ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61867b8922b0dac4c7547bdcd680c9f9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
| filingDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78359c000c23656e8010e03264778447
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29acf53e956dcf3c68d6459cdc28cfd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f40ce6a0602c02ee5ee6508b56934b51 |
| publicationDate |
2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102356831-B1 |
| titleOfInvention |
Pharmaceutical compositions for topical administration in the form of solution and processes for the preparation thereof |
| abstract |
The present invention relates to (i) itraconazole; (ii) ethanol as a volatile vehicle; (iii) benzyl alcohol as a solubilizer; (iv) hydrochloric acid as a protonating agent; (v) pH adjusting agents; and (vi) polyoxyl castor oil or polyoxyl hydrogenated castor oil as a permeation enhancer. The pharmaceutical composition according to the present invention can effectively improve the solubility and stability of itraconazole. In particular, the pharmaceutical composition according to the present invention exhibits a remarkably high skin permeability. Therefore, the pharmaceutical composition according to the present invention can increase the recovery rate of fungal-infected skin lesions while exhibiting low side effects, and thus can be effectively used for topical fungal infections. |
| priorityDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |